IL-18: A potential inflammation biomarker in Wiskott-Aldrich syndrome

Eur J Immunol. 2021 May;51(5):1285-1288. doi: 10.1002/eji.202049024. Epub 2021 Feb 5.

Abstract

Analysis of serum cytokine levels in Wiskott-Aldrich syndrome patients pre- and post- treatment reveals IL-18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid correction correlates with resolution of inflammation and reduction of circulating IL-18, highlighting the importance of actin cytoskeletal regulation of myeloid cells in control of inflammation.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers*
  • Cytokines / metabolism
  • Disease Susceptibility
  • Humans
  • Inflammation Mediators / metabolism*
  • Interleukin-18 / metabolism*
  • Wiskott-Aldrich Syndrome / diagnosis
  • Wiskott-Aldrich Syndrome / etiology
  • Wiskott-Aldrich Syndrome / metabolism*

Substances

  • Biomarkers
  • Cytokines
  • Inflammation Mediators
  • Interleukin-18